PTEN and intrahepatic cholangiocarcinoma: This phase 2, randomized clinical trial enrolled not only ICC patients but also patients with GBC as our further research showed PTEN deficiency could be tested in about 60% of patients with GBC and also facilitate the therapeutic vulnerability to bortezomib.9